  See all
|
Article Summary
|
|
|
ImClone Systems Incorporated, a global leader in the development and commercialization of novel antibodies to treat cancer, announced that its disease-directed randomized Phase 2 clinical trial of IMC-A12 in patients with previously treated HER2-expressing locally advanced or metastatic breast cancer has commenced patient enrollment. IMC-A12 is ImClone's fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody.
--- RESEARCH & DEVELOPMENT TOP ARTICLES ---
Receive free subspecialty "5-minute updates" via email
|
 |
|
Read a Different Specialty |
|
|
|
|
|
Profession Index
|
|
|
|
|
|
|
|
